Lazard Asset Management
ACAD icon

Lazard Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Lazard Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.48M Buy
246,297
+20,075
+9% +$480K 0.01% 539
2025
Q4 		$6.04M Buy
226,222
+53,401
+31% +$1.28M 0.01% 511
2025
Q3 		$3.69M Buy
172,821
+137,250
+386% +$3.25M 0.01% 664
2025
Q2 		$766K Sell
35,571
-151,930
-81% -$2.82M ﹤0.01% 1378
2025
Q1 		$3.11M Buy
187,501
+36,573
+24% +$664K ﹤0.01% 828
2024
Q4 		$2.77M Buy
150,928
+53,885
+56% +$870K ﹤0.01% 779
2024
Q3 		$1.49M Buy
97,043
+63,211
+187% +$1.05M ﹤0.01% 950
2024
Q2 		$549K Buy
33,832
+7,619
+29% +$123K ﹤0.01% 1165
2024
Q1 		$483K Buy
26,213
+17,719
+209% +$439K ﹤0.01% 1064
2023
Q4 		$265K Buy
8,494
+2,133
+34% +$50.9K ﹤0.01% 1300
2023
Q3 		$132K Buy
6,361
+2,236
+54% +$60.7K ﹤0.01% 1527
2023
Q2 		$98K Buy
4,125
+1,088
+36% +$24.2K ﹤0.01% 1585
2023
Q1 		$57K Buy
+3,037
New +$57.8K ﹤0.01% 1751
2022
Q4 		– Sell
-3,689
Closed -$60K – 2356
2022
Q3 		$60K Buy
+3,689
New +$59.7K ﹤0.01% 1710
2022
Q1 		– Sell
-3,115
Closed -$72K – 2304
2021
Q4 		$72K Buy
3,115
+506
+19% +$10.2K ﹤0.01% 1570
2021
Q3 		$43K Buy
+2,609
New +$50.3K ﹤0.01% 1743
2021
Q1 		– Sell
-1,356
Closed -$72K – 1834
2020
Q4 		$72K Hold
1,356
– – ﹤0.01% 1277
2020
Q3 		$55K Buy
+1,356
New +$58.6K ﹤0.01% 1157
2020
Q2 		– Sell
-4,060
Closed -$171K – 1601
2020
Q1 		$171K Sell
4,060
-57,786
-93% -$2.38M ﹤0.01% 920
2019
Q4 		$2.65M Buy
61,846
+61,031
+7,488% +$2.66M ﹤0.01% 632
2019
Q3 		$29K Buy
+815
New +$24.7K ﹤0.01% 1027

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Lazard Asset Management's ACAD Position: Q1 2026 in Review

Lazard Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 8.9% in Q1 2026, buying an estimated $480K and bringing the position to 246,297 shares worth $5.48M. The position accounts for 0.01% of the portfolio, ranked #539.

Lazard Asset Management first reported a position in ACAD in Q3 2019 and has held it in 21 quarters since. The position peaked at $6.04M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Lazard Asset Management held 246,297 shares of Acadia Pharmaceuticals worth $5.48M as of Q1 2026.
  • Lazard Asset Management bought 20,075 Acadia Pharmaceuticals shares in Q1 2026, an estimated $480K.
  • Acadia Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q1 2026, its #539 holding.
  • Lazard Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and has held it in 21 quarters since.
  • Lazard Asset Management's Acadia Pharmaceuticals position peaked at $6.04M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.